AMG 641

AMG 641 is a potent, investigational **calcimimetic** small molecule that functions as an allosteric modulator of the calcium-sensing receptor and is structurally classified as an arylalkylamine. It is more potent than cinacalcet and has a longer half-life in preclinical models. AMG 641 has been shown in rodent models of secondary hyperparathyroidism (especially uremia-induced by dietary adenine) to robustly lower serum parathyroid hormone (PTH), reduce parathyroid gland hyperplasia, prevent vascular calcification, and ameliorate bone abnormalities associated with chronic kidney disease. Its primary mechanism is the allosteric modulation of the calcium-sensing receptor, which suppresses PTH secretion, leading to the observed protective effects against disease complications related to elevated PTH. AMG 641 was developed as a research compound and is not approved for clinical use[1][3].

Other names

(1R)-N-((6-(methyloxy)-4′-(trifluoromethyl)-3-biphenylyl)methyl)-1-phenylethanamine